Publicaciones en las que participa el autor/a Llerena A

1

Estudio del polimorfismo de debrisoquina en una muestra de la población cubana.

Autores

Alvarez M, García-Bacallao L, Labacena-Rodríguez M, Llerena A, Pérez B, Rojo-Hernández D.

10

Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine.

Autores

Alonso ME, Dorado P, Jung-Cook H, Llerena A, López M, Machín E, Monroy-Jaramillo N, Peñas-Lledó EM

11

CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population.

Autores

Dorado P, Heras N, Hernández F, Llerena A, Machín E, Terán E

12

Pharmacogenetics in Latin American populations: regulatory aspects, application to herbal medicine, cardiovascular and psychiatric disorders.

Autores

Dorado P, García-Mesa M, Llerena A, Remírez D, Rodeiro I

13

Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes.

Autores

De Andrés F, Dorado P, Llerena A, Machín E, Naranjo ME, Peñas-Lledó EM

14

Losartan hydroxylation phenotype in an Ecuadorian population: influence of CYP2C9 genetic polymorphism, habits and gender.

Autores

Beltrán LJ, Dorado P, Llerena A, Machín E, Peñas-Lledó EM, Terán E

15

CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans.

Autores

Alvarez M, Calzadilla LR, Dorado P, González I, Llerena A, Peñas-Lledó EM, Pérez B, Ramírez R

16

Eating Disorder Symptoms and CYP2D6 Variation in Cuban Healthy Females: A Report from the Ibero-American Network of Pharmacogenetics.

Autores

Alvarez M, Calzadilla LR, Dorado P, González I, Llerena A, Naranjo ME, Peñas-Lledó EM, Pérez B

17

CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients.

Autores

Alonso E, Dorado P, Jung H, Llerena A, López M, Naranjo ME, Ortega-Vázquez A, Peñas-Lledó EM, Trejo HD

18

Use of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6.

Autores

Abad-Santos F, Carcas-Sansuan A, Dorado P, Estévez-Carrizo FE, González-Vacarezza N, Llerena A, Peñas-Lledó EM

19

Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations.

Autores

Alonso ME, Cobaleda J, Dorado P, Gallego A, Llerena A, López M, Monroy-Jaramillo N, Ortega-Vázquez A, Peñas-Lledó EM, Silva-Zolezzi I

2

Pharmacogenetics of cytochrome P450 in Hispanic populations.

Autores

Dorado P, Llerena A, Suárez-Kurtz G.

20

Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico.

Autores

Dorado P, Galaviz-Hernández C, Lazalde-Ramos BP, Licinio J, Llerena A, Martínez-Fierro ML, Martínez-Sevilla VM, Rangel-Villalobos H, Salazar-Flores J, Sosa-Macías M, Wong ML

21

MDR-1 genotypes and quetiapine pharmacokinetics in healthy volunteers.

Autores

Dorado P, Estévez-Carrizo FE, Fariñas H, González-Vacarezza N, Llerena A, Peñas-Lledó EM

22

Evaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: the CEIBA cocktail.

Autores

De Andrés F, Lazalde-Ramos BP, Llerena A, Naranjo ME, Sosa-Macías M, Tarazona-Santos E

23

Characterization of CYP2D6 genotypes and metabolic profiles in the Portuguese population: pharmacogenetic implications.

Autores

Albuquerque J, Grazina M, Llerena A, Naranjo ME, Ribeiro C

24

Cytochrome P450 genetic polymorphisms of Mexican indigenous populations.

Autores

Llerena A, Sosa-Macías M

25

CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers.

Autores

Alvarez M, Calzadilla LR, Dorado P, González I, Llerena A, Naranjo ME, Peñas-Lledó EM, Pérez B, Ramírez R

26

Present status and perspective of pharmacogenetics in Mexico.

Autores

Cuautle-Rodríguez P, Llerena A, Molina-Guarneros J

27

Pharmacogenetic potential biomarkers for carbamazepine adverse drug reactions and clinical response.

Autores

Cook HJ, Galindo IF, Jaramillo NM, Llerena A, López M, Vázquez AO

28

Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain.

Autores

Alvarez M, Calzadilla LR, Cobaleda J, Dorado P, González I, Llerena A, Peñas-Lledó EM, Pérez B

29

CYP2D6 genetic polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas.

Autores

Alonso E, Corona T, Dorado P, Llerena A, López M, Ochoa A, Ortega-Vázquez A, Peñas-Lledó EM, Yescas P

3

[Study of debrisoquine hydroxylation polymorphism (CYP2D6) in the Cuban population compared to Spaniards].

Autores

Alvarez M, Dorado P, González I, Llerena A, Pérez B

30

CYP2D6 gene polymorphisms and predicted phenotypes in eight indigenous groups from northwestern Mexico.

Autores

Galaviz-Hernández C, Garza-Veloz I, Lazalde-Ramos BP, Llerena A, Martínez-Fierro ML, Naranjo ME, Sosa-Macías M

31

A tribute to josé maría («chema») cantú.

Autores

Llerena A, Penchaszadeh VB, Rojas-Martinez A.

32

Venlafaxine pharmacokinetics focused on drug metabolism and potential biomarkers.

Autores

Alves G, Falcão A., Llerena A, Magalhães P

33

A rapid and simple LC-MS/MS method for the simultaneous evaluation of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 hydroxylation capacity.

Autores

De Andrés F, Llerena A, Sosa-Macías M

34

Relationship between the CYP2C9 IVS8-109A>T polymorphism and high losartan hydroxylation in healthy Ecuadorian volunteers.

Autores

Dorado P, Gallego A, Llerena A, Peñas-Lledó EM, Terán E

35

Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations.

Autores

Fariñas H, Llerena A, Naranjo ME, Peñas-Lledó EM, Rodrigues-Soares F, Tarazona-Santos E

36

Ethnic background and CYP2D6 genetic polymorphisms in Costa Ricans.

Autores

Barrantes R, Céspedes-Garro C, Jiménez-Arce G, Llerena A, Naranjo ME

37

First MEPS/HPLC assay for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in human plasma.

Autores

Alves G, Falcão A., Llerena A, Magalhães P, Rodrigues M

38

CYP2D6 ethnic variability in Hispanics.

Autores

Dorado P, Llerena A, Naranjo ME, Peñas-Lledó EM

39

Regulación europea sobre farmacogenética y farmacogenómica.

Autores

Cáceres MC., Fariñas H, González-Vacarezza N, Llerena A

4

Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers.

Autores

Alvarez M, Dorado P, González I, Llerena A, Peñas-Lledó EM, Pérez B

40

Clinical drug-drug interactions: focus on venlafaxine.

Autores

Alves G, Falcão A., Llerena A, Magalhães P

41

Population pharmacogenetics of Ibero-Latinoamerican populations (MESTIFAR 2014).

Autores

Acosta H., Céspedes-Garro C, Galaviz-Hernández C, Llerena A, Moya GE, Peñas-Lledó EM, Ramírez R, Sosa-Macías M, Tarazona-Santos E, Terán E

42

Interethnic relationships of CYP2D6 variants in native and Mestizo populations sharing the same ecosystem.

Autores

Dorado P, Hernández F, Llerena A, Muñoz-Jimenez S, Ortiz-López R, Perez-Paramo, Rojas-Martinez A.

43

Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes.

Autores

Céspedes-Garro C, De Andrés F, Fariñas H, Fricke-Galindo I, Llerena A, López M, Naranjo ME, Peñas-Lledó EM, Rodrigues-Soares F

44

Pharmacogenetics in Central American healthy volunteers: interethnic variability.

Autores

Barrantes R, Céspedes-Garro C, Fariñas H, Llerena A, Naranjo ME, Ramírez R, Serrano V

45

High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme.

Autores

Apellániz-Ruiz M, Carracedo A, Cascón A, Comino-Méndez I, Currás-Freixes M, De Cubas AA, Grazina M, Ingelman-Sundberg M, Inglada-Pérez L, Llerena A, Mancikova V, Moya GE, Naranjo ME, Opocher G, Rasool M, Rebai A, Robledo M, Rodríguez-Antona C., Sánchez L, Taboada-Echalar P, Triki S

46

Population pharmacogenetics and global health.

Autores

Llerena A

47

Success stories in genomic medicine from resource-limited countries.

Autores

Al Jaibeji H, Ali BR, Brand A, Chantratita W, Forero DA, Laissue P, Lee MT, Llerena A, Lopez-Correa C, Mitropoulos K, Mohamed Z, Patrinos GP., Wonkam A

48

Metabolic phenotype prediction from genotyping data: a bottleneck for the implementation of pharmacogenetics in drug development and clinical practice.

Autores

Llerena A, Peñas-Lledó EM

49

Multiplex Phenotyping for Systems Medicine: A One-Point Optimized Practical Sampling Strategy for Simultaneous Estimation of CYP1A2, CYP2C9, CYP2C19, and CYP2D6 Activities Using a Cocktail Approach.

Autores

Bovera M, De Andrés A, Fariñas H, Llerena A, Terán E

5

[Ibero-American Program of Science and Technology for Development].

Autores

De Camino R, Dos Reis MG, Llerena A, Miguel LJ., Wanden-Berthe C

50

Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations.

Autores

Céspedes-Garro C, De Andrés F, Delgado A, Fricke-Galindo I, Llerena A, López M, Naranjo ME, Peñas-Lledó EM, Rodrigues-Soares F

51

CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.

Autores

Dorado P, Familiar-López I, Fricke-Galindo I, Jung-Cook H, Llerena A, López M, Martínez-Juárez IE, Monroy-Jaramillo N, Ortega-Vázquez A, Peñas-Lledó EM

52

Interethnic variability of pharmacogenetic biomarkers in Mexican healthy volunteers: a report from the RIBEF (Ibero-American Network of Pharmacogenetics and Pharmacogenomics).

Autores

Fricke-Galindo I, Jung-Cook H, Llerena A, López M

53

Relevance of the ancestry for the variability of the Drug-Metabolizing Enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population.

Autores

Barrantes R, Céspedes-Garro C, Fariñas H, Jiménez-Arce G, Llerena A, Naranjo ME, Rodrigues-Soares F, Tarazona-Santos E

54

High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies.

Autores

Cobaleda J, De Andrés F, Delgado A, Llerena A, Naranjo ME, Peñas-Lledó EM

55

Allele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers.

Autores

Dorado P, Fricke-Galindo I, Jung-Cook H, Llerena A, López M, Monroy-Jaramillo N, Ortega-Vázquez A, Peñas-Lledó EM

56

Pharmacogenetic research activity in Central America and the Caribbean: a systematic review.

Autores

Campos ML, Céspedes-Garro C, Duconge J, Fariñas H, Llerena A, Montané-Jaime LK, Naranjo ME, Peñas-Lledó EM, Ramírez R, Roblejo H, Rodrigues-Soares F, Serrano V, Villagrán CI

57

Genetic variability of CYP2C9*2 and CYP2C9*3 in seven indigenous groups from Mexico.

Autores

García-Rodríguez MH, Granados-Silvestre MLÁ, Llerena A, Menjívar M., Ortiz-López R, Peña-Espinoza BI, Rivera-Santiago C, Sánchez-Pozos K

58

Pharmacogenetics and ethnicity: relevance for clinical implementation, clinical trials, pharmacovigilance and drug regulation in Latin America.

Autores

Altamirano C, Céspedes-Garro C, Fariñas H, Fors MM, Galaviz-Hernández C, Hernández F, Jung-Cook H, Llerena A, López M, Moya GE, Ramírez R, Remírez D, Sosa-Macías M, Tarazona-Santos E, Terán E, Waters W

59

To Genotype or Phenotype for Personalized Medicine? CYP450 Drug Metabolizing Enzyme Genotype-Phenotype Concordance and Discordance in the Ecuadorian Population.

Autores

De Andrés F, Hernández F, Llerena A, Terán E

6

Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers.

Autores

Cáceres MC., Cavaco I, Dorado P, Llerena A, Piedade R, Ribeiro V

60

Simultaneous Determination of Cytochrome P450 Oxidation Capacity in Humans: A Review on the Phenotyping Cocktail Approach.

Autores

De Andrés F, Llerena A

61

Predictive biomarkers candidates for patients with metastatic colorectal cancer treated with bevacizumab-containing regimen.

Autores

Alonso I, Arroyo G, De Andrés F, Estévez-Carrizo FE, González-Vacarezza N, Llerena A, Martínez J

62

Can the CEIBA Cocktail Designed for Human Cytochrome P450 Enzymes be Used in the Rat for Drug Interaction Studies?

Autores

Alves G, De Andrés F, Falcão A., Llerena A, Magalhães P

63

An update on HLA alleles associated with adverse drug reactions.

Autores

Fricke-Galindo I, Llerena A, López M

64

Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism.

Autores

Calzadilla LR, De Andrés F, Dorado P, González I, Llerena A, Naranjo ME, Peñas-Lledó EM

65

High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina.

Autores

Dorado P, Ferreiro V, Llerena A, Moya GE, Naranjo ME, Peñas-Lledó EM

66

CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where to from Here for Global Precision Medicine?

Autores

De Andrés F, Llerena A, Naranjo ME, Ramos BPL, Sosa-Macías M

67

Therapeutic Drug Monitoring of Fluoxetine, Norfluoxetine and Paroxetine: A New Tool Based on Microextraction by Packed Sorbent Coupled to Liquid Chromatography.

Autores

Alves G, Falcão A., Llerena A, Magalhães P

68

Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.

Autores

Barrantes R, Calzadilla LR, Estévez-Carrizo FE, Fariñas H, Grazina M, Llerena A, López M, Moya GE, Naranjo ME, Ortiz-López R, Peñas-Lledó EM, Ramírez R, Rodeiro I, Rodrigues-Soares F, Sarmiento AP, Sosa-Macías M, Tarazona-Santos E, Terán E

69

Genetic structure of pharmacogenetic biomarkers in Brazil inferred from a systematic review and population-based cohorts: a RIBEF/EPIGEN-Brazil initiative.

Autores

Andrade PXC, Aquino MM, Barreto ML, Céspedes-Garro C, Horta BL, Kehdy FSG, Lima-Costa MF, Llerena A, Pereira AC, Rodrigues-Soares F, Sampaio-Coelho J, Tarazona-Santos E, Zolini C

7

Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers.

Autores

Dorado P, González I, Llerena A, Pacheco R, Peñas-Lledó EM

70

Pharmacogenetics of adverse reactions to antiepileptic drugs.

Autores

Fricke-Galindo I, Jung-Cook H, Llerena A, López M

71

Carbamazepine adverse drug reactions.

Autores

Fricke-Galindo I, Jung-Cook H, Llerena A, López M

72

Farmacogenética y Farmacogenómica. Cap 63.

Autores

Llerena A, Suárez-Kurtz G.

73

CYP2D6 genetic polymorphism and genetic ancestry on extrapyramidal side-effects of long-term treatment with classical antipsychotics in Cuban patients with schizophrenia.

Autores

Camayd Viera I, Del Toro Bordado L, González-Pal S, Llerena A, Marcheco-Teruel B, Marín Padrón LC, Monzón Benítez G, Roblejo H

74

Frequency of CYP2C9 (*2, *3 and IVS8-109A>T) allelic variants, and their clinical implications, among Mexican patients with diabetes mellitus type 2 undergoing treatment with glibenclamide and metformin.

Autores

Castillo-Nájera F, Cuautle-Rodríguez P, De Andrés F, Llerena A, Molina-Guarneros J, Rodríguez-Rivera N

75

Pharmacogenetics of amfepramone in healthy Mexican subjects reveals potential markers for tailoring pharmacotherapy of obesity: results of a randomised trial.

Autores

De León MB, Gamino-Peña ME, Gómez-Silva M, León-Cachón RBR., León-García A, Llerena A, Piñeyro-Garza E, Vargas-Zapata R

76

Pharmacogenetics and therapeutic drug monitoring of fluoxetine in a real-world setting: A PK/PD analysis of the influence of (non-) genetic factors.

Autores

Alves G, Falcão A., Fortuna A, Llerena A, Magalhães P

78

Real-world clinical characterization of subjects with depression treated with antidepressant drugs focused on (non-) genetic factors, pharmacokinetics, and clinical outcomes: GnG-PK/PD-AD study.

Autores

Alves G, Falcão A., Fortuna A, Llerena A, Magalhães P

79

Farmacogenetica De La Diabetes Mellitus en Latinoamerica: Una Perspectiva Desde La Red Iberoamericana De Farmacogenética. Cap 15.

Autores

Bonilla M, Cuautle P, Llerena A, Molina-Guarneros J, Rodríguez N, Tana L, Terán E

8

Influence of CYP2D6 deletion, multiplication, -1584C–>G, 31G–>A and 2988G–>a gene polymorphisms on dextromethorphan metabolism among Mexican tepehuanos and mestizos.

Autores

Alanis-Bañuelos RE, Dorado P, Lares-Asseff I, Llerena A, Sosa-Macías M

80

Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy.

Autores

Dorado P, Fricke-Galindo I, Jung-Cook H, Llerena A, López M, Martínez-Juárez IE, Monroy-Jaramillo N, Ortega-Vázquez A, Peñas-Lledó EM, Rojas-Tomé IS

81

Challenges and Opportunities for Clinical Pharmacogenetic Research Studies in Resource-limited Settings: Conclusions From the Council for International Organizations of Medical Sciences-Ibero-American Network of Pharmacogenetics and Pharmacogenomics Meeting.

Autores

Diwakar S, Galaviz-Hernández C, Gil JP, Hernández I, Lara-Riegos J, Llerena A, Molina-Guarneros J, Moya GE, Nair S, Peñas-Lledó EM, Rägo L, Ramírez R, Sosa-Macías M, Tarazona-Santos E, Terán E, Verde I

82

High prevalence of CYP2D6 ultrarapid metabolizers in a mestizo Colombian population in relation to Hispanic mestizo populations.

Autores

Borbón A, De Andrés F, Dorado P, Llerena A, Sarmiento AP

83

Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population.

Autores

Altamirano C, De Andrés A, Dorado P, Llerena A, Montes-Mondragón CF, Peñas-Lledó EM, Ramírez R

84

Relevance of NR1I2 variants on carbamazepine therapy in Mexican Mestizos with epilepsy at a tertiary-care hospital.

Autores

Dorado P, Fricke-Galindo I, Jung-Cook H, Llerena A, López M, Martínez-Juárez IE, Monroy-Jaramillo N, Ortega-Vázquez A, Peñas-Lledó EM, Rojas-Tomé IS

84

Última

Autores

Altamirano C, De Andrés A, Dorado P, Llerena A, Montes-Mondragón CF, Peñas-Lledó EM, Ramírez R

9

CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards.

Autores

Alanis-Bañuelos RE, Dorado P, Lares-Asseff I, Licinio J, Llerena A, Peñas-Lledó EM, Sosa-Macías M, Wong ML